Vimpat (lacosamide) NDC 0131-2477

NDC codes

FDA NDC Directory

Product NDC (as listed)0131-2477Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00131-2477Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0131-2477-35	00131247735	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0131-2477-35)Marketed from May 26, 2009
0131-2477-60	00131247760	6 BLISTER PACK in 1 CARTON (0131-2477-60) / 10 TABLET, FILM COATED in 1 BLISTER PACKMarketed from May 26, 2009
0131-2477-99	00131247799	1 BLISTER PACK in 1 CARTON (0131-2477-99) / 14 TABLET, FILM COATED in 1 BLISTER PACKMarketed from May 26, 2009

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Vimpat
Generic name (nonproprietary): lacosamide
Active ingredients: Lacosamide — 50 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: UCB, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022253
Marketing start: May 26, 2009
Listing expires: Dec 31, 2027
DEA schedule: CV
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0131-2477_51a12988-3e4b-c52b-e063-6394a90a7415SPL ID 51a12988-3e4b-c52b-e063-6394a90a7415SPL set ID 9e79b42c-38a3-4b2c-a196-a5a1948250e2RxCUI 809974, 809984, 809987, 809990, 809992, 809994, 809996, 809998, 810000, 810002, 993856, 995156UNII 563KS2PQY5

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400131247735 followed by a unit qualifier and the quantity

Package 00131-2477-35. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 12, 2026.

Indications (excerpt from the label)

VIMPAT is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures VIMPAT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures VIMPAT is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022253

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022253
Product	Strength	Form · route	Labeler	Product NDC
Vimpatlacosamide	Lacosamide 150 mg/1	Tablet, Film coatedOral	UCB, Inc.	0131-2479
Vimpatlacosamide	Lacosamide 100 mg/1	Tablet, Film coatedOral	UCB, Inc.	0131-2478
Vimpatlacosamide	Lacosamide 200 mg/1	Tablet, Film coatedOral	UCB, Inc.	0131-2480